Market Snapshot

BSE Sensex: 77288.5 -0.93%
BSE 500: 33495.53 -0.79%
BSE 200: 10580.53 -0.73%
BSE 100: 24522.84 -0.77%
BSE MidCap: 41624.73 -0.67%
BSE SmallCap: 46385.7 -1.45%
BSE BANKEX: 58934.51 -1.08%
BSE IT: 36628.34 -1.11%
Nifty 50: 23486.85 -0.77%
Nifty 500: 21275.45 -0.76%
Nifty 200: 12951.45 -0.69%
Nifty 100: 23990.4 -0.70%
Nifty Midcap 100: 51646.15 -0.62%
Nifty Small 100: 15936.75 -1.07%
Nifty IT: 37336.7 -0.98%
Nifty PSU Bank: 6142.8 -1.19%

News:

Maruti Suzuki board approves t...
Siemens spurts on NCLT nod for...
One Mobikwik Systems incorpora...
Bharat Dynamics gains on baggi...
Shraddha Prime Projects jumps ...

Marksans Pharma Ltd Share Price – NSE / BSE
Pharmaceuticals, Small Cap

Invest

26 Mar 2025 | 04:14 PM

219.51

-6.49 (-2.87%)

Add to Watchlist

This awesome feature is still in our labs.
Set Alert

This awesome feature is still in our labs.

Outperforms Index

52.12%

Return (1Y)

Beaten Nifty 50 by 45.38%
More Volatile

3.42%

Standard Deviation (1Y)

Higher than Nifty 50 by 2.54%
Consistent Performer

8/12

Months

beaten Nifty 50
AxisDirect View

No View

52 Week High-Low

359

130

News & Announcements

Marksans Pharma's Goa facility receives Australian TGA approval
7 days ago

Marksans Pharma's Goa facility receives Australian TGA approval

20 - Mar - 2025 12:00 AM | 7 days ago

Marksans Pharma announced that its manufacturing facility located at Plot A-1, Phase 1-A, Verna Industrial Estate, Verna, Goa has been approved by Australian TGA for manufacture of pharmaceutical formulations in Solid Dosage Forms of Tablets and hard Capsules for Australian markets.

The products will be manufactured at the above facility in Goa India and marketed & distributed in Australian markets through the Company's subsidiary Nova Pharmaceuticals Australasia.
Powered by Capital Market - Live News
Marksans Pharma rises after receiving regulatory nod for supplying pharma products to Australia
7 days ago

Marksans Pharma rises after receiving regulatory nod for supplying pharma products to Australia

20 - Mar - 2025 12:00 AM | 7 days ago

The pharmaceutical formulations include solid dosage forms of tablets and hard capsules.
The products will be manufactured at the aforementioned facility located at Verna Industrial Estate, Verna, Goa, and marketed & distributed in Australian markets through the company?s subsidiary Nova Pharmaceuticals Australasia.
Marksans Pharma is primarily engaged in the business of research, manufacture, marketing, and sale of pharmaceutical formulations.
The company reported a 25.6% increase in consolidated net profit to Rs 104.56 crore on a 16.3% rise in revenue from operations to Rs 681.85 crore in Q3 FY25 over Q3 FY24.

Powered by Capital Market - Live News
Relonchem receives UK MHRA marketing authorization for Baclofen 10 mg Tablets
8 days ago

Relonchem receives UK MHRA marketing authorization for Baclofen 10 mg Tablets

19 - Mar - 2025 12:00 AM | 8 days ago

Marksans Pharma announced that its wholly owned subsidiary Relonchem has received Marketing Authorization for the product Baclofen 10 mg Tablets from UK MHRA.
Powered by Capital Market - Live News
Marksans Pharma gains after arm gets nod for Baclofen tablets from UK MHRA
8 days ago

Marksans Pharma gains after arm gets nod for Baclofen tablets from UK MHRA

19 - Mar - 2025 12:00 AM | 8 days ago

Baclofen Tablets are used to help relax specific muscles in the body, providing relief from spasms, cramping, and muscle tightness caused by conditions such as multiple sclerosis and certain spinal injuries. While Baclofen does not cure these conditions, it may enhance the effectiveness of other treatments, including physical therapy, in improving patients' overall condition.
Marksans Pharma is primarily engaged in the business of research, manufacture, marketing, and sale of pharmaceutical formulations.
The company reported a 25.6% increase in consolidated net profit to Rs 104.56 crore on a 16.3% rise in revenue from operations to Rs 681.85 crore in Q3 FY25 over Q3 FY24.
Powered by Capital Market - Live News

Price vs Volume

Stock Trivia

FII shareholding in Marksans Pharma Ltd has increased by 6.2% since past 3 Months
MF shareholding in Marksans Pharma Ltd has increased by 4.04% since past 3 Months
FII shareholding in Marksans Pharma Ltd has increased by 136.74% since past 1 Year
MF shareholding in Marksans Pharma Ltd has decreased by -17.65% since past 1 Year

Peer Comparison on Risk - Return

Thanks for Liking, Please spread your love by sharing...

General Notifications

My Notifications

Research Notifications

Marksans Pharma Ltd Share Price – NSE / BSE Pharmaceuticals, Small Cap

219.51 -6.49 (-2.87%)

News & Announcements

Price vs Volume

Stock Trivia

Marksans Pharma Ltd Share Price – NSE / BSE
Pharmaceuticals, Small Cap

219.51

-6.49 (-2.87%)